Wilson A L, Seibert K, Brandon S, Cragoe E J, Limbird L E
Department of Pharmacology, Vanderbilt University, School of Medicine, Nashville, Tennessee 37232.
Mol Pharmacol. 1991 Apr;39(4):481-6.
The unglycosylated alpha 2B subtype of the alpha 2-adrenergic receptor found in NG-108-15 cells possesses allosteric regulation of adrenergic ligand binding by monovalent cations and 5-amino-substituted amiloride analogs. These findings demonstrate that allosteric modulation of adrenergic ligand binding is not a property unique to the alpha 2A subtype. The observation that amiloride analogs as well as monovalent cations can modulate adrenergic ligand binding to the nonglycosylated alpha 2B subtype indicates that charge shielding due to carbohydrate moieties does not play a role in this allosteric modulation but, rather, these regulatory effects result from interactions of cations and amiloride analogs with the protein moiety of the receptor. Furthermore, the observation that both alpha 2A and alpha 2B receptor subtypes are modulated by amiloride analogs suggests that structural domains that are conserved between the two are likely to be involved in this allosteric modulation.
在NG-108-15细胞中发现的α2 - 肾上腺素能受体的非糖基化α2B亚型具有单价阳离子和5 - 氨基取代的阿米洛利类似物对肾上腺素能配体结合的变构调节作用。这些发现表明,肾上腺素能配体结合的变构调节并非α2A亚型所特有的性质。阿米洛利类似物以及单价阳离子能够调节肾上腺素能配体与非糖基化α2B亚型的结合这一观察结果表明,碳水化合物部分引起的电荷屏蔽在这种变构调节中不起作用,相反,这些调节作用是由阳离子和阿米洛利类似物与受体的蛋白质部分相互作用导致的。此外,α2A和α2B受体亚型均受阿米洛利类似物调节这一观察结果表明,两者之间保守的结构域可能参与了这种变构调节。